Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Videos|June 11, 2021
Working as a Part of a Care Team is an Important Skill for Research Pharmacists
Clinical trial participants often have even more questions than patients receiving standard-of-care treatments, so working within the team to answer their questions and provide optimal care is essential for research pharmacists.
Advertisement
In his work with Cancer Treatment Centers of America, research pharmacist Brian Wortz, PharmD, said he works within a broad care team of physicians, nurses, data coordinators, study coordinators, and others.
Clinical trial participants often have even more questions than patients receiving standard-of-care treatments, so working within the team to answer their questions and provide optimal care is essential for research pharmacists, Wortz said.
Advertisement
Related to this article
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5